12 Longevity Clinics and Treatments That Aim to Extend Human Lifespan

3. Epigenetic reprogramming (Yamanaka factors)

Epigenetic reprogramming traces back to Shinya Yamanaka’s discovery that a set of transcription factors can reset a cell’s identity. In partial reprogramming, researchers aim to roll back cellular aging markers without losing cell specialization. Animal studies have shown promising lifespan and healthspan effects when reprogramming is tightly controlled. Clinics referencing this science may emphasize its potential to address age-related decline at a foundational level, but important safety questions remain for humans—most notably, how to prevent cells from becoming pluripotent in ways that raise cancer risk or tissue dysfunction. Regulatory agencies are focused on clear safety signals before approving human treatments that alter cellular identity, so anything offered now in a clinical setting should be treated as experimental and confined to formal trials. Prospective patients should ask whether proposed interventions are part of registered clinical trials, what endpoints are being measured, and what independent oversight exists. Right now, partial reprogramming is an exciting research avenue with real promise, but it’s not yet a standard clinical therapy you can safely access outside tightly controlled studies.

4. Senolytic therapies

Senolytics target senescent cells—cells that have stopped dividing and secrete inflammatory signals that can harm nearby tissue. In lab models, clearing these cells has improved organ function and increased healthy lifespan markers. A number of clinical trials are testing different senolytic drugs and repurposed compounds, and some clinics have begun offering off-label regimens or experimental protocols under physician oversight. That practice sits in a grey zone: patients may access potential benefits sooner, but they also assume risks that formal trials exist to quantify. Common safety concerns include unintended effects on tissue regeneration and immune responses. If a clinic recommends senolytic treatment, ask whether the protocol is part of a trial, whether baseline and follow-up measures will be taken, and how adverse events are tracked. Look for transparency about which drugs are proven for specific conditions and which are speculative. Right now, senolytics are one of the most active translational areas in longevity science—promising, but not yet a universal, proven clinical standard.